NMI-300

N/A

Report date: 2023/07/20 14:14:09

Base Information

Drug NameNMI-300
Drug Alias NameNMI-300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDiagnostic imaging enhancersDNA synthesis inhibitorsDNA cross linking agents +[4] 
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNemucore Medical Innovations
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNemucore Medical Innovations
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A